| 白羽霞,管晓东,王宝敏,史录文,李文胜.我国发展药物大品种的关键因素分析与规制政策探讨[J].中国药事,2015,(11): |
| 我国发展药物大品种的关键因素分析与规制政策探讨 |
| Key factors and regulation policies for development of drug superstars in China |
| 投稿时间：2015-07-15 修订日期：2015-07-15 |
| DOI： |
| 中文关键词: 药物大品种 扎根理论 专家访谈 政策规制 |
| 英文关键词: drug superstars grounded theory expert interview regulation policy |
| 基金项目: |
|
| 摘要点击次数: 1650 |
| 全文下载次数: 614 |
| 中文摘要: |
| 目的：探讨我国发展药物大品种的关键因素和规制政策。方法：选取政府、企业、学术机构各单位的专家学者进行访谈,然后采用扎根理论分析访谈资料。结果：界定出药物大品种的概念范围,明确了我国建立药物大品种的必要性,分析出药物大品种改造的产业政策,并提出我国药物大品种改造的政策规制模型。结论：政府建立政策、完善制度,引导企业发展；企业加强自身创新能力、开拓国际市场,推进大品种的改造。 |
| 英文摘要: |
| OBJECTIVE：To discuss key factors and regulation policies for development of drug superstars in China. METHODS：Interviewed several experts from governments, enterprises and research institutions, and then analyzed the interview data by grounded theory. RESULTS：Defined the concept of drug superstars, cleared the necessity of drug superstars, analyzed the regulation policy and developed model for development of drug superstars. CONCLUSION：Governments should establish policy and improve system to guide enterprises to develop drug superstars. And enterprises should enhance their innovation capability and explore the international market to promote the reform of drug superstars in China. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|